Loading...

Gregory Light

Title(s)Professor In Residence, Psychiatry
SchoolHealth Sciences
Address9500 Gilman Drive #0804
La Jolla CA 92093
Phone619-543-2496
vCardDownload vCard
    Other Positions
    Title(s)Deputy Vice Chair, Psychiatry Education and Training


    Collapse Biography 
    Collapse Awards and Honors
    Brain & Behavior Research Foundation2018Top Advancement & Breakthrough of 2018
    UC San Diego Faculty Mentor Program2015Outstanding Mentor Award
    Brain & Behavior Research Foundation2014Sidney R. Baer, Jr. International Prize for Innovative and Promising Schizophrenia Research

    Collapse Overview 
    Collapse Overview
    Dr. Gregory Light is a Professor and Deputy Vice Chair of Education and Training in the UCSD Department of Psychiatry. Dr. Light also serves as the Director of Mental Health Research and the Director of the Mental Illness, Research, Education and Clinical Center (MIRECC) at the VA San Diego Healthcare System. In these roles, he provide leadership, supervision, and administrative support across several clinical, education, and multidisciplinary research programs. Dr. Light has published over 130 peer-reviewed papers (h-index=55). This work has been prominently featured in policy reports from the Institute of Medicine for next-generation strategies for personalized treatments of psychotic disorders.

    Psychotic disorders have devastating and often life-long consequences for approximately 2% of the global population. Most psychiatric interventions are implemented in the absence of knowledge about individual variation in important domains of brain function that might influence therapeutic response and outcome. This “one-size-fits-all” approach to treatment is problematic, with treatment failure occurring far too often and incurring substantial cost to the patient, family, therapist and larger social system. To “bend the curve” on the individual outcomes and societal impact of chronic psychotic illness, we must advance our understanding of the neural substrates of the illness features that most strongly contribute to poor outcomes, and use this information to guide mechanistically informed, personalized treatments. Dr. Light's program of research has advanced the use of neurophysiological biomarkers to develop precision medicine trials for psychosis patients that are: 1) effectively delivered in “real-world” community centers; and 2) informed by objective, reliable, validated, and low-cost biomarkers for identifying patients most likely to benefit (or not) from treatments. Findings support large-scale biomarker-guided trials to prevent or ameliorate illness in high-risk cohorts or treatment refractory populations. This program ultimately aims to develop and apply personalized biomarker assessment tools to deliver the “right treatment” to the “right person” at the “right time.”

    Dr. Light's career has maintained a focus on developing scientists for careers in academic medicine and neuroscience. As Deputy Vice Chair of Psychiatry Education and Training in the UCSD Department of Psychiatry, Dr.Light assists in the oversight of over 25 Programs. As Center Director of the Mental Illness, Research, Education, and Clinical Center (MIRECC) at the VA San Diego Healthcare System, he oversees 2 successful post-doctoral fellowship programs and coordinates the activities of trainees at many levels. Dr. Light also provides frequent lectures and serves on independent study, thesis, and dissertation committees across departments at UCSD including: Psychiatry, Psychology, Neuroscience, Cognitive Science, and Biology. Dr. Light also oversees medical student research studies. I serve as a mentor for 3 prominent international neuropsychiatric research organizations: Society of Biological Psychiatry, the American College of Neuropsychopharmacology, and International Congress on Schizophrenia Research.

    Collapse Research 
    Collapse Research Activities and Funding
    Memantine augmentation of cognitive training in schizophrenia
    NIH R33MH125114Feb 16, 2021 - Dec 31, 2023
    Role: Principal Investigator
    Accelerated Inflammaging in Schizophrenia
    NIH R01MH094151May 1, 2012 - Apr 30, 2017
    Role: Principal Investigator
    Pathway(s) From Genes to Functional Deficits of Schizophrenia Patients
    NIH R01MH079777Jul 25, 2007 - May 31, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Abnormally Large Baseline P300 Amplitude Is Associated With Conversion to Psychosis in Clinical High Risk Individuals With a History of Autism: A Pilot Study. Front Psychiatry. 2021; 12:591127. Foss-Feig JH, Guillory SB, Roach BJ, Velthorst E, Hamilton H, Bachman P, Belger A, Carrion R, Duncan E, Johannesen J, Light GA, Niznikiewicz M, Addington JM, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan T, Perkins D, Seidman LJ, Stone WS, Tsuang M, Walker EF, Woods S, Bearden CE, Mathalon DH. PMID: 33633603.
      View in: PubMed   Mentions:
    2. Unique contributions of sensory discrimination and gamma synchronization deficits to cognitive, clinical, and psychosocial functional impairments in schizophrenia. Schizophr Res. 2021 Jan 22; 228:280-287. Koshiyama D, Miyakoshi M, Thomas ML, Joshi YB, Molina JL, Tanaka-Koshiyama K, Sprock J, Braff DL, Swerdlow NR, Light GA. PMID: 33493776.
      View in: PubMed   Mentions:    Fields:    
    3. Source Decomposition of the Frontocentral Auditory Steady-State Gamma Band Response in Schizophrenia Patients and Healthy Subjects. Psychiatry Clin Neurosci. 2021 Jan 20. Koshiyama D, Miyakoshi M, Joshi YB, Nakanishi M, Tanaka-Koshiyama K, Sprock J, Light GA. PMID: 33470494.
      View in: PubMed   Mentions:    Fields:    
    4. Sources of the frontocentral mismatch negativity and P3a responses in schizophrenia patients and healthy comparison subjects. Int J Psychophysiol. 2021 Jan 13; 161:76-85. Koshiyama D, Miyakoshi M, Joshi YB, Nakanishi M, Tanaka-Koshiyama K, Sprock J, Light GA. PMID: 33453303.
      View in: PubMed   Mentions:    Fields:    
    5. Decreased Gamma Auditory Steady-State Response Is Associated With Impaired Real-World Functioning in Unmedicated Patients at Clinical High Risk for Psychosis. Clin EEG Neurosci. 2020 Dec 23; 1550059420982706. Ahmed S, Lepock JR, Mizrahi R, Bagby RM, Gerritsen CJ, Korostil M, Light GA, Kiang M. PMID: 33356513.
      View in: PubMed   Mentions:    Fields:    
    6. Neural network dynamics underlying gamma synchronization deficits in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Dec 16; 110224. Koshiyama D, Miyakoshi M, Joshi YB, Molina JL, Tanaka-Koshiyama K, Braff DL, Swerdlow NR, Light GA. PMID: 33340619.
      View in: PubMed   Mentions:    Fields:    
    7. Neurophysiologic Characterization of Resting State Connectivity Abnormalities in Schizophrenia Patients. Front Psychiatry. 2020; 11:608154. Koshiyama D, Miyakoshi M, Tanaka-Koshiyama K, Joshi YB, Molina JL, Sprock J, Braff DL, Light GA. PMID: 33329160.
      View in: PubMed   Mentions:
    8. Gamma oscillations predict pro-cognitive and clinical response to auditory-based cognitive training in schizophrenia. Transl Psychiatry. 2020 Nov 23; 10(1):405. Molina JL, Thomas ML, Joshi YB, Hochberger WC, Koshiyama D, Nungaray JA, Cardoso L, Sprock J, Braff DL, Swerdlow NR, Light GA. PMID: 33230190.
      View in: PubMed   Mentions:    Fields:    
    9. Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia. Neuropsychopharmacology. 2020 Nov 17. Desai A, Benner L, Wu R, Gertsik L, Maruff P, Light GA, Uz T, Marek GJ, Zhu T. PMID: 33203954.
      View in: PubMed   Mentions:    Fields:    
    10. Heritability of acoustic startle magnitude and latency from the consortium on the genetics of schizophrenia. Schizophr Res. 2020 Nov 11. Greenwood TA, Swerdlow NR, Sprock J, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Duncan E. PMID: 33189519.
      View in: PubMed   Mentions:    Fields:    
    11. Reliability of mismatch negativity event-related potentials in a multisite, traveling subjects study. Clin Neurophysiol. 2020 Dec; 131(12):2899-2909. PMID: 33160266.
      View in: PubMed   Mentions:    Fields:    
    12. Memantine effects on auditory discrimination and training in schizophrenia patients. Neuropsychopharmacology. 2020 12; 45(13):2180-2188. Swerdlow NR, Bhakta SG, Talledo J, Kotz J, Roberts BZ, Clifford RE, Thomas ML, Joshi YB, Molina JL, Light GA. PMID: 32961542.
      View in: PubMed   Mentions:    Fields:    
    13. Abnormal Spontaneous Gamma Power Is Associated With Verbal Learning and Memory Dysfunction in Schizophrenia. Front Psychiatry. 2020; 11:832. Tanaka-Koshiyama K, Koshiyama D, Miyakoshi M, Joshi YB, Molina JL, Sprock J, Braff DL, Light GA. PMID: 33110410.
      View in: PubMed   Mentions:
    14. Hierarchical Pathways from Sensory Processing to Cognitive, Clinical, and Functional Impairments in Schizophrenia. Schizophr Bull. 2020 Aug 28. Koshiyama D, Thomas ML, Miyakoshi M, Joshi YB, Molina JL, Tanaka-Koshiyama K, Sprock J, Braff DL, Swerdlow NR, Light GA. PMID: 32856089.
      View in: PubMed   Mentions: 1     Fields:    
    15. Evidence of Slow Neural Processing, Developmental Differences and Sensitivity to Cannabis Effects in a Sample at Clinical High Risk for Psychosis From the NAPLS Consortium Assessed With the Human Startle Paradigm. Front Psychiatry. 2020; 11:833. Cadenhead KS, Duncan E, Addington J, Bearden C, Cannon TD, Cornblatt BA, Mathalon D, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Bauchman P, Belger A, Carrión RE, Donkers F, Johannesen J, Light G, Niznikiewicz M, Nunag J, Roach B. PMID: 33005152.
      View in: PubMed   Mentions:
    16. A distributed frontotemporal network underlies gamma-band synchronization impairments in schizophrenia patients. Neuropsychopharmacology. 2020 12; 45(13):2198-2206. Koshiyama D, Miyakoshi M, Joshi YB, Molina JL, Tanaka-Koshiyama K, Sprock J, Braff DL, Swerdlow NR, Light GA. PMID: 32829382.
      View in: PubMed   Mentions: 2     Fields:    
    17. Deficits in auditory predictive coding in individuals with the psychosis risk syndrome: Prediction of conversion to psychosis. J Abnorm Psychol. 2020 Aug; 129(6):599-611. PMID: 32757603.
      View in: PubMed   Mentions:    Fields:    
    18. Contextualizing the road to recovery: A novel method of assessing outcome trajectories in clinical trials. Psychol Serv. 2020 Jul 13. Treichler EBH, Cardoso L, Du Y, Nungaray J, Hochberger WC, Joshi YB, Sprock J, Cohen AN, Light GA. PMID: 32658511.
      View in: PubMed   Mentions:    Fields:    
    19. Abnormal Effective Connectivity Underlying Auditory Mismatch Negativity Impairments in Schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Nov; 5(11):1028-1039. Koshiyama D, Miyakoshi M, Joshi YB, Molina JL, Tanaka-Koshiyama K, Sprock J, Braff DL, Swerdlow NR, Light GA. PMID: 32830097.
      View in: PubMed   Mentions: 1     Fields:    
    20. The effects of age and sex on cognitive impairment in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS) study. PLoS One. 2020; 15(5):e0232855. Lee J, Green MF, Nuechterlein KH, Swerdlow NR, Greenwood TA, Hellemann GS, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Gur RC, Gur RE, Braff DL. PMID: 32401791.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Stability of mismatch negativity event-related potentials in a multisite study. Int J Methods Psychiatr Res. 2020 06; 29(2):e1819. Roach BJ, Hamilton HK, Bachman P, Belger A, Carrión RE, Duncan E, Johannesen J, Kenney JG, Light G, Niznikiewicz M, Addington J, Bearden CE, Owens EM, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman L, Tsuang M, Walker EF, Woods SW, Mathalon DH. PMID: 32232944.
      View in: PubMed   Mentions: 1     Fields:    
    22. Memantine Effects on Electroencephalographic Measures of Putative Excitatory/Inhibitory Balance in Schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 06; 5(6):562-568. Molina JL, Voytek B, Thomas ML, Joshi YB, Bhakta SG, Talledo JA, Swerdlow NR, Light GA. PMID: 32340927.
      View in: PubMed   Mentions: 4     Fields:    
    23. Impaired Sensory Processing During Low-Oxygen Exposure: A Noninvasive Approach to Detecting Changes in Cognitive States. Front Psychiatry. 2020; 11:12. Seech TR, Funke ME, Sharp RF, Light GA, Blacker KJ. PMID: 32082202.
      View in: PubMed   Mentions:
    24. Selection criteria for neurophysiologic biomarkers to accelerate the pace of CNS therapeutic development. Neuropsychopharmacology. 2020 01; 45(1):237-238. Light GA, Swerdlow NR. PMID: 31506611.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. Genome-wide Association of Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia (COGS) Study. JAMA Psychiatry. 2019 12 01; 76(12):1274-1284. Greenwood TA, Lazzeroni LC, Maihofer AX, Swerdlow NR, Calkins ME, Freedman R, Green MF, Light GA, Nievergelt CM, Nuechterlein KH, Radant AD, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Gur RC, Gur RE, Braff DL. PMID: 31596458.
      View in: PubMed   Mentions: 4     Fields:    
    26. Oscillatory biomarkers of early auditory information processing predict cognitive gains following targeted cognitive training in schizophrenia patients. Schizophr Res. 2020 01; 215:97-104. Hochberger WC, Thomas ML, Joshi YB, Molina J, Treichler EBH, Nungaray J, Cardoso L, Sprock J, Swerdlow N, Light GA. PMID: 31759809.
      View in: PubMed   Mentions: 2     Fields:    
    27. Deviation from expected cognitive ability is a core cognitive feature of schizophrenia related to neurophysiologic, clinical and psychosocial functioning. Schizophr Res. 2020 01; 215:300-307. Hochberger WC, Thomas ML, Joshi YB, Swerdlow NR, Braff DL, Gur RE, Gur RC, Light GA. PMID: 31744751.
      View in: PubMed   Mentions:    Fields:    
    28. Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome. JAMA Psychiatry. 2019 11 01; 76(11):1187-1197. Hamilton HK, Roach BJ, Bachman PM, Belger A, Carrion RE, Duncan E, Johannesen JK, Light GA, Niznikiewicz MA, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Cannon TD, Mathalon DH. PMID: 31389974.
      View in: PubMed   Mentions: 7     Fields:    
    29. Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients. Neuropsychopharmacology. 2019 12; 44(13):2277-2284. Swerdlow NR, Bhakta SG, Talledo J, Benster L, Kotz J, Lavadia M, Light GA. PMID: 31445502.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Mismatch negativity reveals plasticity in cortical dynamics after 1-hour of auditory training exercises. Int J Psychophysiol. 2019 11; 145:40-47. Perez VB, Miyakoshi M, Makeig SD, Light GA. PMID: 31176741.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    31. Nonlinear dynamics underlying sensory processing dysfunction in schizophrenia. Proc Natl Acad Sci U S A. 2019 02 26; 116(9):3847-3852. Lainscsek C, Sampson AL, Kim R, Thomas ML, Man K, Lainscsek X, Swerdlow NR, Braff DL, Sejnowski TJ, Light GA. PMID: 30808768.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    32. Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients. Schizophr Res. 2019 06; 208:384-389. Joshi YB, Thomas ML, Hochberger WC, Bismark AW, Treichler EBH, Molina J, Nungaray J, Cardoso L, Sprock J, Swerdlow NR, Light GA. PMID: 30738698.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. Relationships between cognitive event-related brain potential measures in patients at clinical high risk for psychosis. Schizophr Res. 2020 Dec; 226:84-94. Lepock JR, Ahmed S, Mizrahi R, Gerritsen CJ, Maheandiran M, Drvaric L, Bagby RM, Korostil M, Light GA, Kiang M. PMID: 30683525.
      View in: PubMed   Mentions: 2     Fields:    
    34. Divergence of subjective and performance-based cognitive gains following cognitive training in schizophrenia. Schizophr Res. 2019 08; 210:215-220. Treichler EBH, Thomas ML, Bismark AW, Hochberger WC, Tarasenko M, Nungaray J, Cardoso L, Joshi YB, Zhang W, Sprock J, Swerdlow N, Cohen AN, Light GA. PMID: 30660574.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. Decomposing the constituent oscillatory dynamics underlying mismatch negativity generation in schizophrenia: Distinct relationships to clinical and cognitive functioning. Int J Psychophysiol. 2019 11; 145:23-29. Hochberger WC, Joshi YB, Zhang W, Thomas ML, Braff DL, Swerdlow NR, Light GA. PMID: 30586570.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia. Front Psychiatry. 2018; 9:554. Joshi YB, Light GA. PMID: 30510520.
      View in: PubMed   Mentions:
    37. Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia. Neuropsychopharmacology. 2019 02; 44(3):606-612. Hochberger WC, Joshi YB, Thomas ML, Zhang W, Bismark AW, Treichler EBH, Tarasenko M, Nungaray J, Sprock J, Cardoso L, Swerdlow N, Light GA. PMID: 30377381.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    38. Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care. Schizophr Res. 2018 12; 202:378-384. Thomas ML, Bismark AW, Joshi YB, Tarasenko M, Treichler EBH, Hochberger WC, Zhang W, Nungaray J, Sprock J, Cardoso L, Tiernan K, Attarha M, Braff DL, Vinogradov S, Swerdlow N, Light GA. PMID: 30055883.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    39. Computerized cognitive training is associated with improved psychosocial treatment engagement in schizophrenia. Schizophr Res. 2018 12; 202:341-346. Thomas ML, Treichler EBH, Bismark A, Shiluk AL, Tarasenko M, Zhang W, Joshi YB, Sprock J, Cardoso L, Tiernan K, Light GA. PMID: 29929773.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. Reverse translated and gold standard continuous performance tests predict global cognitive performance in schizophrenia. Transl Psychiatry. 2018 04 12; 8(1):80. Bismark AW, Thomas ML, Tarasenko M, Shiluk AL, Rackelmann SY, Young JW, Light GA. PMID: 29643355.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    41. Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge. Schizophr Res. 2018 09; 199:285-291. Swerdlow NR, Bhakta SG, Light GA. PMID: 29627173.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    42. Sensorimotor gating deficits in schizophrenia: Advancing our understanding of the phenotype, its neural circuitry and genetic substrates. Schizophr Res. 2018 08; 198:1-5. PMID: 29525460.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    43. Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap. Neuropsychopharmacology. 2018 01; 43(1):230-231. Young JW, Light GA. PMID: 29192660.
      View in: PubMed   Mentions:    Fields:    
    44. Web-Based Tools and Mobile Applications To Mitigate Burnout, Depression, and Suicidality Among Healthcare Students and Professionals: a Systematic Review. Acad Psychiatry. 2018 Feb; 42(1):109-120. PMID: 29256033.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    45. Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors. Int J Neuropsychopharmacol. 2017 12 01; 20(12):979-987. Bhakta SG, Light GA, Talledo JA, Balvaneda B, Hughes E, Alvarez A, Rana BK, Young JW, Swerdlow NR. PMID: 29020372.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    46. Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients. Neuropsychopharmacology. 2018 03; 43(4):708-717. Swerdlow NR, Bhakta SG, Talledo JA, Franz DM, Hughes EL, Rana BK, Light GA. PMID: 29154367.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    47. Mismatch negativity impairment is associated with deficits in identifying real-world environmental sounds in schizophrenia. Schizophr Res. 2018 01; 191:5-9. PMID: 28927552.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    48. Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. Schizophr Bull. 2017 07 01; 43(4):872-880. PMID: 27798224.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    49. Relationship between effortful motivation and neurocognition in schizophrenia. Schizophr Res. 2018 03; 193:69-76. Bismark AW, Thomas ML, Tarasenko M, Shiluk AL, Rackelmann SY, Young JW, Light GA. PMID: 28673753.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    50. Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension. Schizophr Res. 2018 08; 198:6-15. PMID: 28549722.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    51. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia. Neuropsychopharmacology. 2017 Dec; 42(13):2633-2639. PMID: 28425497.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    52. Evidence of systematic attenuation in the measurement of cognitive deficits in schizophrenia. J Abnorm Psychol. 2017 Apr; 126(3):312-324. PMID: 28277736.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    53. Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia. Neuropsychopharmacology. 2017 Oct; 42(11):2206-2213. PMID: 28139679.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    54. Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. JAMA Psychiatry. 2017 Jan 01; 74(1):37-46. PMID: 27926742.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    55. Neurophysiological Characterization of Attentional Performance Dysfunction in Schizophrenia Patients in a Reverse-Translated Task. Neuropsychopharmacology. 2017 May; 42(6):1338-1348. PMID: 27917869.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    56. Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study. Schizophr Res. 2016 07; 174(1-3):1-9. PMID: 27132484.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    57. Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy. Psychopharmacology (Berl). 2016 06; 233(12):2399-410. PMID: 27076209.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    58. Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia. Schizophr Res. 2016 Apr; 172(1-3):123-30. PMID: 26851143.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    59. Animal Models of Deficient Sensorimotor Gating in Schizophrenia: Are They Still Relevant? Curr Top Behav Neurosci. 2016; 28:305-25. PMID: 27311762.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    60. Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. Schizophr Res. 2016 Jan; 170(1):30-40. PMID: 26597662.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    61. Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History. Am J Psychiatry. 2016 Apr 01; 173(4):385-91. PMID: 26441157.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    62. Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis. Neuropsychopharmacology. 2016 Jan; 41(2):419-30. PMID: 26062785.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    63. Bending the curve on psychosis outcomes. Lancet Psychiatry. 2015 May; 2(5):365-367. PMID: 26360262.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    64. GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders. Neuropsychopharmacology. 2015 Nov; 40(12):2715-26. PMID: 25907107.
      View in: PubMed   Mentions: 10     Fields:    Translation:Animals
    65. Neurocognitive performance in family-based and case-control studies of schizophrenia. Schizophr Res. 2015 Apr; 163(1-3):17-23. PMID: 25432636.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    66. Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Ann N Y Acad Sci. 2015 May; 1344:105-19. PMID: 25752648.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimals
    67. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):38-46. PMID: 25749017.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    68. Factor structure and heritability of endophenotypes in schizophrenia: findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophr Res. 2015 Apr; 163(1-3):73-9. PMID: 25682549.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    69. Electroencephalographic biomarkers of psychosis: present and future. Biol Psychiatry. 2015 Jan 15; 77(2):87-9. PMID: 25524305.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    70. Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies. Schizophr Res. 2015 Apr; 163(1-3):47-52. PMID: 25553977.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    71. California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):32-7. PMID: 25497440.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    72. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):63-72. PMID: 25449710.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    73. The auditory brain-stem response to complex sounds: a potential biomarker for guiding treatment of psychosis. Front Psychiatry. 2014; 5:142. PMID: 25352811.
      View in: PubMed   Mentions:
    74. The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):53-62. PMID: 25306203.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    75. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. Neuroimage Clin. 2014; 6:424-37. PMID: 25379456.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    76. Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications. Schizophr Res. 2015 Apr; 163(1-3):24-31. PMID: 25248939.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    77. Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study. Schizophr Bull. 2014 Nov; 40(6):1404-11. PMID: 24903414.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    78. Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings. Psychiatry Res. 2014 Sep 30; 219(1):67-71. PMID: 24913833.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    79. Not all distraction is bad: working memory vulnerability to implicit socioemotional distraction correlates with negative symptoms and functional impairment in psychosis. Schizophr Res Treatment. 2014; 2014:320948. PMID: 24724026.
      View in: PubMed   Mentions:
    80. Is there an association between advanced paternal age and endophenotype deficit levels in schizophrenia? PLoS One. 2014; 9(2):e88379. PMID: 24523888.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    81. Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res. 2014 Feb; 152(2-3):503-12. PMID: 24405980.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    82. Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomark Med. 2014; 8(1):9-14. PMID: 24325220.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    83. Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle. Curr Top Behav Neurosci. 2014; 21:293-314. PMID: 24850080.
      View in: PubMed   Mentions: 12     Fields:    
    84. Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in mice. Transl Psychiatry. 2013 Nov 12; 3:e324. PMID: 24217494.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimals
    85. Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats. Behav Brain Res. 2013 Nov 15; 257:118-28. PMID: 24076151.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    86. Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders. Proc Natl Acad Sci U S A. 2013 Sep 17; 110(38):15175-6. PMID: 23995447.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimals
    87. Between-site reliability of startle prepulse inhibition across two early psychosis consortia. Neuroreport. 2013 Aug 07; 24(11):626-30. PMID: 23799460.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    88. Coupling of gene expression in medial prefrontal cortex and nucleus accumbens after neonatal ventral hippocampal lesions accompanies deficits in sensorimotor gating and auditory processing in rats. Neuropharmacology. 2013 Dec; 75:38-46. PMID: 23810830.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    89. Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2013 May; 170(5):521-32. PMID: 23511790.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    90. Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr Res. 2013 May; 146(1-3):326-35. PMID: 23490760.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    91. Sex differences in familiality effects on neurocognitive performance in schizophrenia. Biol Psychiatry. 2013 May 15; 73(10):976-84. PMID: 23395246.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    92. Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses. Neuroimage. 2013 Feb 01; 66:594-603. PMID: 23085112.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    93. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012; 7(7):e39434. PMID: 22802938.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    94. Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats. Psychopharmacology (Berl). 2012 Dec; 224(3):349-62. PMID: 22700037.
      View in: PubMed   Mentions: 9     Fields:    Translation:Animals
    95. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol. 2012 Oct; 123(10):1942-9. PMID: 22608970.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    96. Sensory and sensorimotor gating deficits after neonatal ventral hippocampal lesions in rats. Dev Neurosci. 2012; 34(2-3):240-9. PMID: 22572564.
      View in: PubMed   Mentions: 9     Fields:    Translation:Animals
    97. Older patients with schizophrenia: does military veteran status matter? Am J Geriatr Psychiatry. 2012 Mar; 20(3):248-56. PMID: 22354115.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    98. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry. 2012 May 15; 71(10):873-80. PMID: 22361076.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    99. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One. 2012; 7(1):e29630. PMID: 22253750.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    100. ? oscillations in schizophrenia: mechanisms and clinical significance. Brain Res. 2011 Sep 21; 1413:98-114. Sun Y, Farzan F, Barr MS, Kirihara K, Fitzgerald PB, Light GA, Daskalakis ZJ. PMID: 21840506.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimals
    101. Automatic sensory information processing abnormalities across the illness course of schizophrenia. Psychol Med. 2012 Jan; 42(1):85-97. PMID: 21740622.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    102. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2011 Sep; 168(9):930-46. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Gur RE, Gur RC, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. PMID: 21498463.
      View in: PubMed   Mentions: 121     Fields:    Translation:Humans
    103. Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2011 May; 128(1-3):102-10. Stone WS, Giuliano AJ, Tsuang MT, Braff DL, Cadenhead KS, Calkins ME, Dobie DJ, Faraone SV, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Roe AH, Schork NJ, Siever LJ, Silverman JM, Swerdlow NR, Thomas AR, Tsuang DW, Turetsky BI, Seidman LJ. PMID: 21288694.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    104. Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr Psychiatry Rep. 2010 Dec; 12(6):572-8. Rissling AJ, Makeig S, Braff DL, Light GA. PMID: 20857348.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    105. Superior size-weight illusion performance in patients with schizophrenia: evidence for deficits in forward models. Schizophr Res. 2010 Aug; 121(1-3):101-6. Williams LE, Ramachandran VS, Hubbard EM, Braff DL, Light GA. PMID: 19931421.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    106. Electroencephalography (EEG) and event-related potentials (ERPs) with human participants. Curr Protoc Neurosci. 2010 Jul; Chapter 6:Unit 6.25.1-24. Light GA, Williams LE, Minow F, Sprock J, Rissling A, Sharp R, Swerdlow NR, Braff DL. PMID: 20578033.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    107. Reduced multisensory integration in patients with schizophrenia on a target detection task. Neuropsychologia. 2010 Aug; 48(10):3128-36. Williams LE, Light GA, Braff DL, Ramachandran VS. PMID: 20600181.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    108. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res. 2010 Jun; 119(1-3):175-82. Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R. PMID: 20382002.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    109. Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study. Psychophysiology. 2010 Sep; 47(5):846-56. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Meichle SP, Millard SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. PMID: 20374545.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    110. Sensory and sensorimotor gating-disruptive effects of apomorphine in Sprague Dawley and Long Evans rats. Behav Brain Res. 2010 Apr 02; 208(2):560-5. Breier MR, Lewis B, Shoemaker JM, Light GA, Swerdlow NR. PMID: 20080128.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    111. Neurophysiological measures of sensory registration, stimulus discrimination, and selection in schizophrenia patients. Curr Top Behav Neurosci. 2010; 4:283-309. Rissling AJ, Light GA. PMID: 21312404.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    112. The relationship between preattentive sensory processing deficits and age in schizophrenia patients. Clin Neurophysiol. 2009 Nov; 120(11):1949-1957. Kiang M, Braff DL, Sprock J, Light GA. PMID: 19786365.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    113. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One. 2009; 4(1):e4227. Young JW, Light GA, Marston HM, Sharp R, Geyer MA. PMID: 19156216.
      View in: PubMed   Mentions: 60     Fields:    Translation:Animals
    114. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry. 2008 Dec 15; 64(12):1051-9. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, Cadenhead KS, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Calkins ME. PMID: 18701089.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    115. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008 Aug; 199(3):331-88. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. PMID: 18568339.
      View in: PubMed   Mentions: 197     Fields:    Translation:HumansAnimals
    116. Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2008 Aug; 103(1-3):218-28. Horan WP, Braff DL, Nuechterlein KH, Sugar CA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. PMID: 18406578.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    117. Advances in endophenotyping schizophrenia. World Psychiatry. 2008 Feb; 7(1):11-8. Braff DL, Greenwood TA, Swerdlow NR, Light GA, Schork NJ. PMID: 18458787.
      View in: PubMed   Mentions:
    118. An event-related brain potential study of direct and indirect semantic priming in schizophrenia. Am J Psychiatry. 2008 Jan; 165(1):74-81. Kiang M, Kutas M, Light GA, Braff DL. PMID: 18056222.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    119. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry. 2007 Nov; 64(11):1242-50. Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Schork NJ. PMID: 17984393.
      View in: PubMed   Mentions: 168     Fields:    Translation:Humans
    120. Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci. 2007 Oct; 19(10):1624-32. Light GA, Swerdlow NR, Braff DL. PMID: 18271737.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    121. Relationship between P50 suppression and the cortical silent period. Neuroreport. 2007 Sep 17; 18(14):1503-6. Möller B, Light GA, Fitzgerald PB, Snyder JS, Chen R, Daskalakis ZJ. PMID: 17712283.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    122. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res. 2007 Sep; 95(1-3):134-42. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL. PMID: 17662577.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    123. Cognitive, neurophysiological, and functional correlates of proverb interpretation abnormalities in schizophrenia. J Int Neuropsychol Soc. 2007 Jul; 13(4):653-63. Kiang M, Light GA, Prugh J, Coulson S, Braff DL, Kutas M. PMID: 17521483.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    124. Electrophysiological insights into conceptual disorganization in schizophrenia. Schizophr Res. 2007 May; 92(1-3):225-36. Kiang M, Kutas M, Light GA, Braff DL. PMID: 17383161.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    125. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2007 May; 92(1-3):237-51. Swerdlow NR, Sprock J, Light GA, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Mintz J, Olincy A, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. PMID: 17346930.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    126. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry. 2007 May 15; 61(10):1204-7. Braff DL, Light GA, Swerdlow NR. PMID: 17161386.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    127. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry. 2006 Dec; 63(12):1325-35. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL. PMID: 17146007.
      View in: PubMed   Mentions: 123     Fields:    Translation:Humans
    128. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. 2007 Jan; 33(1):69-94. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. PMID: 17135482.
      View in: PubMed   Mentions: 196     Fields:    Translation:Humans
    129. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull. 2007 Jan; 33(1):33-48. Calkins ME, Dobie DJ, Cadenhead KS, Olincy A, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. PMID: 17035358.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    130. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res. 2007 Jan; 89(1-3):320-9. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Light GA, Meichle SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. PMID: 17023145.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    131. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006 Dec 01; 60(11):1231-40. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff DL. PMID: 16893524.
      View in: PubMed   Mentions: 144     Fields:    Translation:Humans
    132. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology. 2006 Mar; 31(3):506-15. Swerdlow NR, Geyer MA, Shoemaker JM, Light GA, Braff DL, Stevens KE, Sharp R, Breier M, Neary A, Auerbach PP. PMID: 16123772.
      View in: PubMed   Mentions: 18     Fields:    Translation:Animals
    133. Event-related gamma activity in schizophrenia patients during a visual backward-masking task. Am J Psychiatry. 2005 Dec; 162(12):2330-6. Wynn JK, Light GA, Breitmeyer B, Nuechterlein KH, Green MF. PMID: 16330598.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    134. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry. 2005 Sep; 162(9):1741-3. Light GA, Braff DL. PMID: 16135637.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    135. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol. 2005 Jul-Aug; 28(4):179-84. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA. PMID: 16062097.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    136. P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment. Biol Psychiatry. 2005 Jun 15; 57(12):1504-9. Cadenhead KS, Light GA, Shafer KM, Braff DL. PMID: 15953486.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    137. On the waveform of the acoustic startle blink in the paradigm of prepulse inhibition - methodological and physiological aspects. Neuropsychobiology. 2005; 52(1):24-7. Meincke U, Light GA, Geyer MA, Braff DL. PMID: 15942260.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    138. Prepulse inhibition of perceived stimulus intensity: paradigm assessment. Biol Psychol. 2005 May; 69(2):133-47. Swerdlow NR, Stephany NL, Talledo J, Light G, Braff DL, Baeyens D, Auerbach PP. PMID: 15804542.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    139. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry. 2005 Apr 01; 57(7):817-20. Braff DL, Light GA, Ellwanger J, Sprock J, Swerdlow NR. PMID: 15820241.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    140. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005 Feb; 62(2):127-36. Light GA, Braff DL. PMID: 15699289.
      View in: PubMed   Mentions: 130     Fields:    Translation:Humans
    141. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin Neurosci. 2005; 7(2):125-35. Braff DL, Light GA. PMID: 16262208.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimals
    142. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl). 2004 Jun; 174(1):75-85. Braff DL, Light GA. PMID: 15118804.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimals
    143. Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res. 2004 Apr 15; 126(1):51-61. Meincke U, Light GA, Geyer MA, Braff DL, Gouzoulis-Mayfrank E. PMID: 15081627.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    144. Visual masking as a probe for abnormal gamma range activity in schizophrenia. Biol Psychiatry. 2003 Jun 15; 53(12):1113-9. Green MF, Mintz J, Salveson D, Nuechterlein KH, Breitmeyer B, Light GA, Braff DL. PMID: 12814862.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    145. Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype? Am J Psychiatry. 2002 May; 159(5):869-71. Cadenhead KS, Light GA, Geyer MA, McDowell JE, Braff DL. PMID: 11986147.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    146. Measuring P50 suppression and prepulse inhibition in a single recording session. Am J Psychiatry. 2001 Dec; 158(12):2066-8. Light GA, Braff DL. PMID: 11729028.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    147. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001 Apr 15; 49(1-2):171-8. Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow NR. PMID: 11343875.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    148. Schizophrenia patients demonstrate a dissociation on declarative and non-declarative memory tests. Schizophr Res. 2000 Dec 15; 46(2-3):167-74. Perry W, Light GA, Davis H, Braff DL. PMID: 11120428.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    149. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry. 2000 May; 157(5):767-71. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL. PMID: 10784470.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    150. Do self-reports of perceptual anomalies reflect gating deficits in schizophrenia patients? Biol Psychiatry. 2000 Mar 01; 47(5):463-7. Light GA, Braff DL. PMID: 10704957.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    151. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am J Psychiatry. 2000 Jan; 157(1):55-9. Cadenhead KS, Light GA, Geyer MA, Braff DL. PMID: 10618013.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    152. Human and animal studies of schizophrenia-related gating deficits. Curr Psychiatry Rep. 1999 Oct; 1(1):31-40. Light GA, Braff DL. PMID: 11122903.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimals
    153. Amphetamine disrupts P50 suppression in normal subjects. Biol Psychiatry. 1999 Oct 01; 46(7):990-6. Light GA, Malaspina D, Geyer MA, Luber BM, Coleman EA, Sackeim HA, Braff DL. PMID: 10509182.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    154. The "incredible shrinking" P50 event-related potential. Biol Psychiatry. 1998 Jun 15; 43(12):918-20. Light GA, Braff DL. PMID: 9627748.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    Gregory's Networks
    Concepts (339)
    Derived automatically from this person's publications.
    _
    Co-Authors (54)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _